Kimberly Green, DO
Hematology & Oncology · Charlotte, NCNPI 1447424197
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,758 of the $9,395 with a category attached, or 61.3%. It is spread thinly across 41 manufacturers, the largest accounting for just 21.1%. Reporting peaked in 2019 at $3,331 and has fallen 91.8% since, to $273 in 2025.
Across 246 payments — averaging $38.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$2K
- Janssen Scientific Affairs, LLC$1K
- Sanofi$683
- Incyte Corporation$586
- Novartis$584
- E.r. Squibb & Sons, L.L.C.$499
- plus $4K from 35 others
Across 48 payments — averaging $19,121 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$857K
- AbbVie$61K
- Incyte Corporation$245
What the payments were for
- Consulting fees$3,02532%
- Food & beverage$5,75861%
- Education$1732%
- Gifts$4395%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 2 | $1,984 |
| Janssen Scientific Affairs, LLC | 2 | $1,225 |
| Sanofi | 8 | $683 |
| Incyte Corporation | 8 | $586 |
| Novartis | 36 | $584 |
| E.r. Squibb & Sons, L.L.C. | 24 | $499 |
| Abiomed | 10 | $483 |
| Pfizer | 24 | $350 |
| Bristol Myers Squibb | 9 | $312 |
| Merck | 19 | $285 |
| Genentech USA, Inc. | 19 | $264 |
| AbbVie | 3 | $253 |
| Kyowa Kirin, Inc. | 4 | $215 |
| Amgen | 13 | $206 |
| Johnson & Johnson | 4 | $158 |
| Jazz Pharmaceuticals Inc. | 2 | $144 |
| Seagen Inc. | 7 | $142 |
| Adaptive Biotechnologies Corporation | 1 | $132 |
| Eisai Inc. | 6 | $112 |
| Taiho Oncology, Inc. | 5 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $96 |
| Lilly USA, LLC | 6 | $96 |
| Astellas Pharma US Inc | 4 | $70 |
| Bayer | 4 | $63 |
| AstraZeneca(2 entities) | 3 | $41 |
| Secura Bio, Inc. | 3 | $33 |
| Tesaro, Inc. | 2 | $30 |
| Rigel Pharmaceuticals, Inc. | 2 | $26 |
| Lexicon Pharmaceuticals, Inc. | 2 | $26 |
| Puma Biotechnology, Inc. | 2 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Fennec Pharmaceuticals, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| GSK | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $14 |
| Dova Pharmaceuticals | 1 | $14 |
| Partner Therapeutics, Inc. | 1 | $13 |
| Advanced Accelerator Applications | 1 | $12 |
| Gilead | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,395 in reported general payments places this provider in the 75th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XospataGilteritinib Fumarate | 28 | $653,058 |
| RezurockBelumosudil Mesylate | 18 | $635,567 |
| OjjaaraMomelotinib Dihydrochloride | 26 | $616,084 |
| RevlimidLenalidomide | 30 | $466,154 |
| PomalystPomalidomide | 19 | $393,127 |
| CresembaIsavuconazonium Sulfate | 17 | $106,164 |
| Plerixafor | 22 | $84,274 |
| VenclextaVenetoclax | 28 | $84,092 |
| OxycontinOxycodone Hcl | 13 | $20,227 |
| Posaconazole | 17 | $15,061 |
| Deferasirox | 17 | $10,158 |
| Acyclovir | 212 | $2,556 |
| ValacyclovirValacyclovir Hcl | 13 | $1,575 |
| Dexamethasone | 110 | $1,146 |
| Oxycodone Hcl | 47 | $702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXospata, Cresemba | $70 | $759,22245 claims |
| GSKOjjaara | $16 | $616,08426 claims |
| Bristol Myers SquibbRevlimid | $312 | $466,15430 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $499 | $393,12719 claims |
| AbbVieVenclexta | $253 | $84,09228 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $14 | $2,556212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Charlotte
- Shelbi AtrashCharlotte$994K
- Nasfat ShehadehCharlotte$68K
- Jennifer AtlasCharlotte$59K
- Joseph MerrimanCharlotte$50K
- Justin FavaroCharlotte$33K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.